Fullerton Fund Management Co Ltd. Boosts Holdings in Intuitive Surgical, Inc. $ISRG

Fullerton Fund Management Co Ltd. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12,156.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,908 shares of the medical equipment provider’s stock after acquiring an additional 73,305 shares during the quarter. Intuitive Surgical comprises about 1.6% of Fullerton Fund Management Co Ltd.’s holdings, making the stock its 24th largest position. Fullerton Fund Management Co Ltd.’s holdings in Intuitive Surgical were worth $40,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in Intuitive Surgical by 2.1% during the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after purchasing an additional 670,302 shares during the last quarter. State Street Corp boosted its holdings in shares of Intuitive Surgical by 1.2% in the 2nd quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock valued at $8,451,223,000 after purchasing an additional 182,871 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Intuitive Surgical by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock valued at $4,429,590,000 after buying an additional 109,904 shares during the period. Norges Bank acquired a new stake in shares of Intuitive Surgical during the 2nd quarter worth $2,569,260,000. Finally, Invesco Ltd. raised its position in shares of Intuitive Surgical by 4.8% in the 2nd quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock worth $2,402,488,000 after buying an additional 201,159 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Henry L. Charlton sold 13,731 shares of Intuitive Surgical stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $580.00, for a total transaction of $7,963,980.00. Following the sale, the executive vice president owned 3,056 shares of the company’s stock, valued at $1,772,480. The trade was a 81.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Brian Edward Miller sold 3,500 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $575.00, for a total transaction of $2,012,500.00. Following the completion of the transaction, the executive vice president owned 5,758 shares in the company, valued at $3,310,850. This represents a 37.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 109,043 shares of company stock worth $60,816,225. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $542.32 on Friday. The company has a market cap of $194.41 billion, a P/E ratio of 71.74, a PEG ratio of 5.03 and a beta of 1.68. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The business’s 50-day simple moving average is $529.62 and its 200 day simple moving average is $506.00.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the business earned $1.84 EPS. Intuitive Surgical’s quarterly revenue was up 22.9% compared to the same quarter last year. Analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analysts Set New Price Targets

ISRG has been the topic of a number of research analyst reports. Piper Sandler lifted their target price on Intuitive Surgical from $595.00 to $610.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Leerink Partners raised their price objective on Intuitive Surgical from $593.00 to $600.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Royal Bank Of Canada set a $625.00 target price on Intuitive Surgical and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Sanford C. Bernstein reissued an “outperform” rating and set a $685.00 target price on shares of Intuitive Surgical in a research report on Tuesday, October 21st. Finally, BTIG Research raised their price target on shares of Intuitive Surgical from $529.00 to $589.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $608.79.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.